Avid Bioservices (Avid Bioservices) ROCE % : -8.11% (As of Jan. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Avid Bioservices's annualized ROCE % for the quarter that ended in Jan. 2024 was -8.11%.

Avid Bioservices ROCE % Historical Data

The historical data trend for Avid Bioservices's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices ROCE % Chart

Avid Bioservices Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

ROCE %

Get a 7-Day Free Trial

-9.42

-17.67

9.60

5.59

1.26

Avid Bioservices Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															3.49	1.30	-2.02	-11.73	-8.11

Avid Bioservices ROCE % Calculation

Avid Bioservices's annualized ROCE % for the fiscal year that ended in Apr. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2023 )		(A: Apr. 2022 )		(A: Apr. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2023 )		(A: Apr. 2022 )		(A: Apr. 2023 )
	=	4.603	/	( ( (429.843 - 75.761)	+	(451.054 - 73.709) )	/ 2 )
	=	4.603	/	( (354.082	+	377.345)	/ 2 )
	=	4.603	/	365.7135
	=	1.26 %

Avid Bioservices's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-24.732	/	( ( (454.642 - 76.937)	+	(455.227 - 222.887) )	/ 2 )
	=	-24.732	/	( ( 377.705	+	232.34 )	/ 2 )
	=	-24.732	/	305.0225
	=	-8.11 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Avid Bioservices (NAS:CDMO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Avid Bioservices ROCE % Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avid Bioservices (Avid Bioservices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TEHN:Germany

Address

14191 Myford Road, Tustin, CA, USA, 92780

Website

https://www.avidbio.com

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Executives

Matthew R. Kwietniak	officer: Chief Commercial Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri	officer: Chief Operations Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart	officer: Chief Financial Officer	2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell	officer: V.P., General Counsel	14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone	director	3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green	director, officer: President & CEO	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen	director
Esther M. Alegria	director	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth	director	500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg	officer: Principal Fin. & Acct. Officer	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780